Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.57 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 8/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.53 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.53 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.53 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.53 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.53 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.53 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.53 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.53 |
| ▸ | KRAS | P01116 | 2/20 | 0.52 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21010336 | 1.00 | TGM2 (0.57) | TGM2FUT5P2RY2P2RY6ENPP1 | |
| SCHEMBL20597816 | 0.99 | TGM2 (0.57) | TGM2FUT5P2RY2P2RY6ENPP1 | |
| SCHEMBL17586590 | 0.99 | TGM2 (0.57) | TGM2FUT5P2RY2P2RY6ENPP1 | |
| SCHEMBL18769111 | 0.96 | TGM2 (0.59) | TGM2FUT5P2RY2P2RY6P2RY1 | |
| SCHEMBL18769341 | 0.96 | TGM2 (0.59) | TGM2FUT5P2RY2P2RY6P2RY1 | |
| SCHEMBL18769512 | 0.96 | TGM2 (0.59) | TGM2FUT5P2RY2P2RY6P2RY1 | |
| SCHEMBL25433573 | 0.95 | TGM2 (0.55) | TGM2FUT5P2RY2P2RY6ENPP1 | |
| SCHEMBL18769344 | 0.94 | TGM2 (0.57) | TGM2FUT5P2RY2P2RY6NT5E | |
| Ammonia Solution, Strong SCHEMBL22134216 | 0.94 | DCPS (0.57) | TGM2FUT5P2RY2P2RY6ENPP1 | |
| SCHEMBL19592001 | 0.93 | P2RY2 (0.57) | TGM2FUT5P2RY2P2RY6NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109727-A1 | RNA CONSTRUCTS AND USES THEREOF | BioNTech SE (DE) | 2026-04-23 | — | — | US | disclosed |
| US-20260009026-A1 | Capped RNA and Method for Producing Same, Apparatus for Producing Protein, and Method for Producing Protein | JAPAN SCIENCE & TECH AGENCY (JP) | 2026-01-08 | — | — | US | disclosed |
| WO-2025217207-A1 | SYSTEMS AND METHODS FOR EVALUATION OF GASTROINTESTINAL DISEASE AND APPLICATIONS THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250215043-A1 | RNA CAP ANALOGS AND METHODS OF USE | MEDICI THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| CN-120092014-A | RNA constructs and uses thereof | 生物技术欧洲股份公司 | 2025-06-03 | — | — | CN | disclosed |
| US-20250171489-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | TRILINK BIOTECHNOLOGIES, LLC (US) | 2025-05-29 | — | — | US | disclosed |
| CN-119677859-A | Capped RNA, method for producing same, device for producing protein, and method for producing protein | 国立研究开发法人科学技术振兴机构 | 2025-03-21 | — | — | CN | disclosed |
| WO-2025053250-A1 | METHOD FOR PRODUCING PROTEIN OR PEPTIDE, METHOD FOR PRODUCING 5'-CAPPED POLYNUCLEOTIDE, AND REAGENT FOR USE IN SAID PRODUCTION METHODS | 国立大学法人東海国立大学機構 | 2025-03-13 | — | — | WO | disclosed |
| EP-4509608-A1 | CAPPED RNA AND METHOD FOR PRODUCING SAME, APPARATUS FOR PRODUCING PROTEIN, AND METHOD FOR PRODUCING PROTEIN | Japan Science and Technology Agency (JP) | 2025-02-19 | — | — | EP | disclosed |
| EP-4469465-A1 | TRINUCLEOTIDE CAP ANALOGS AND METHODS OF USE THEREOF | TriLink BioTechnologies, LLC (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023147352-A1 | TRINUCLEOTIDE CAP ANALOGS AND METHODS OF USE THEREOF | TRILINK BIOTECHNOLOGIES, LLC (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230130423-A1 | NOVEL MRNA 5'-END CAP ANALOGS, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE | UNIWERSYTET WARSZAWSKI (PL) | 2023-04-27 | — | — | US | disclosed |
| CN-115768437-A | Capping compounds, compositions and methods of use thereof | 磨石生物公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2023025073-A1 | CAPPED ANALOG AND USE THEREOF | 上海兆维科技发展有限公司 | 2023-03-02 | — | — | WO | disclosed |
| EP-4138854-A2 | CAPPING COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | Gritstone bio, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2023282245-A1 | METHOD FOR PURIFYING NUCLEOTIDES, DEVICE FOR PURIFYING NUCLEOTIDES, HYDROPHOBIC REAGENT, AND HYDROPHOBIC SUBSTRATE | 国立研究開発法人科学技術振興機構 | 2023-01-12 | — | — | WO | disclosed |
| EP-4103578-A1 | NOVEL MRNA 5'-END CAP ANALOGS MODIFIED WITHIN PHOSPHATE RESIDUES, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE | Uniwersytet Warszawski (PL) | 2022-12-21 | — | — | EP | disclosed |
| EP-4103577-A1 | NOVEL MRNA 5'-END CAP ANALOGS, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE | Uniwersytet Warszawski (PL) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021162566-A1 | NOVEL MRNA 5'-END CAP ANALOGS MODIFIED WITHIN PHOSPHATE RESIDUES, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE | UNIWERSYTET WARSZAWSKI (PL) | 2021-08-19 | — | — | WO | disclosed |
| WO-2021162567-A1 | NOVEL MRNA 5'-END CAP ANALOGS, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE | UNIWERSYTET WARSZAWSKI (PL) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130423-A1 | NOVEL MRNA 5'-END CAP ANALOGS, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE | RNGTT, RNMT, NSUN3 | TGM2 3118/4885FUT5 2895/4885P2RY2 4196/4885 |
| US-20250215043-A1 | RNA CAP ANALOGS AND METHODS OF USE | RNGTT, RNMT, NSUN2 | TGM2 3831/4885FUT5 1497/4885P2RY2 3925/4885 |
| US-20250171489-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | RNGTT, RNMT, NT5C3B | TGM2 1420/4885FUT5 263/4885P2RY2 2018/4885 |
| US-20260009026-A1 | Capped RNA and Method for Producing Same, Apparatus for Producing Protein, and Method for Producing Protein | RNGTT, RNMT, NSUN3 | TGM2 3538/4885FUT5 3495/4885P2RY2 3331/4885 |
| US-20260109727-A1 | RNA CONSTRUCTS AND USES THEREOF | RNGTT, RNMT, NSUN3 | TGM2 2526/4885FUT5 1302/4885P2RY2 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.